Melt away stubborn belly fat with our Belly Fat Burner for Men and Women! Designed to target abdominal fat, this supplement boosts metabolism and supports your fitness journey. https://t.co/QEPVHEOJ03
#FitnessGoals#HealthyLiving#fatburner#fitness#gym#weightloss#diet
๐ Start your weight loss journey with our Diet Weight Loss Supplement Pills, Orlistat 60mg Capsules Starter Pack! Formulated to support your goals, these capsules aid in fat absorption, promoting effective weight management. https://t.co/z9QpN52dW1
#WeightLoss#HealthyLiving
Achieve your weight loss goals with our powerful combo: Keto Ultra Weight Loss Supplement and 100% Pure White Kidney Bean Extract! Keto Ultra aids ketosis for fat burning. https://t.co/rLBOBJAkHX
#WeightLoss#KetoDiet#weightlosssupplement
Among trials I'd like to see replicated is this one of the antibody bimagrumab.
In a sample of diabetics, it led to semaglutide-like weight loss with zero lean mass loss by end of study. In fact, lean mass went up, consistent with bimagrumab mimicking myostatin deficiency.
FLOW trial results announced by NovoNordisk
โผ๏ธ24% risk reduction in kidney disease-related events with semaglutide in T2DM and CKD
https://t.co/iHBLDNXwbu
#FLOWTrial
๐ Grab the breakthrough in weight loss with Semaglutide injection! Shedding pounds has never been easier or more effective. Start your journey to a healthier you today! ๐ช ๐ https://t.co/1KZEMP5uCzโ
โ
#Semaglutide#injections#nutrition#diet#weightlosstips#fitness
@CMichaelGibson Sounds great Dr. Gibson. #Wegovy does this indirectly by the benefits of weight reduction on #CV health or any possible direct effect is also present?
@novonordisk
BIG NEWS:
Novo Nordisk's #Wegovy wins FDA approval for cutting heart disease risks in overweight patients in move that could expand insurance coverage https://t.co/fY2BRRnO1i
๐จ NEWS ALERT๐จ
๐semaglutide โคต๏ธ 24% adverse #kidney outcomes in people with #type2diabetes#CKD
๐ driven by both โคต๏ธ Kidney and โคต๏ธ๐ events
๐ Tolerability similar to trials with 1mg samaglutide
๐จ #Wow ๐จ
๐https://t.co/MOpn9AprwS
Announcement from @novonordisk re the FLOW trial:
Semaglutide reduced the risk of 50% decline in eGFR, kidney failure, or death due to kidney or cardiovascular disease by 24%
Results to be presented this year by trial PI @VladoPerkovic & colleagues
https://t.co/hZT4iPxRvl